NVMDF News and Press, Novamind Inc. From 11/29/21

Novamind (OTCPK:NVMDF): FQ1 GAAP EPS of -$0.07. Revenue of $1.86M (+113% Y/Y) Press Release Total working capital of $6.83M to fund operations. For further details see: Novamind reports FQ1 results

Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice Total revenue of $1,857,750, +113% when compared to same period last year Total working capital of $6,834,011 to fund operations TORONTO, ON / ACCESSWIRE / November 29, 2021 / Novamin...

TORONTO, ON / ACCESSWIRE / November 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched a new logo and announced that the Company will unite its subsidiaries and brands un...

TORONTO, ON / ACCESSWIRE / November 16, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has signed a Letter of Intent ("LOI") to acquire Foundations for Change ,...

TORONTO, ON / ACCESSWIRE / November 15, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will participate in Mind Medicine Australia's International Summit on Psychedelic Therapies for Me...

TORONTO, ON / ACCESSWIRE / November 12, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today it has leased a new clinic location in Utah (the "Wheeler Park Clinic"), and will ...

Blue Cross added to list of insurance companies covering IV ketamine treatments at Novamind TORONTO, ON / ACCESSWIRE / November 10, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is ...

TORONTO, ON / ACCESSWIRE / November 8, 2021 /  Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that the Ontario Securities Commission (the " OSC ") issued a...

Novamind (OTCPK:NVMDF): FY GAAP EPS of -C$0.20. Revenue of C$6.06M Press Release For further details see: Novamind reports FY results

Industry-leading revenue, $6,069,247 in FY2021 Total working capital of $9,680,431 to fund operations­­ Expanded network to six clinics and three clinical research sites Contracted for eight clinical trials Granted DEA Schedule 1 licenses for psilocybin researc...